How much funding has Verdiva Bio raised?

Verdiva Bio has raised $411.0M in total funding, most recently a Series A round.

Who are Verdiva Bio's investors?

Verdiva Bio's investors include Forbion Capital Partners, General Atlantic, RA Capital Management, OrbiMed, Logos Capital, Eli Lilly.

When was Verdiva Bio founded?

Verdiva Bio was founded in 2024.

Where is Verdiva Bio headquartered?

Verdiva Bio is headquartered in London, United Kingdom.

What industry is Verdiva Bio in?

Verdiva Bio operates in Life Sciences, Biotech, Therapeutics.

How many employees does Verdiva Bio have?

Verdiva Bio has 11-50 employees.

Verdiva Bio

Transforming lives by accelerating innovation in cardiometabolic health

London, United Kingdom · Founded 2024 · $411.0M raised

Life Sciences

Biotech

Therapeutics

Headquarters: London
Employees: 11–50
Founded: 2024
Business Model: B2B

Website: verdivabio.com
Total Funding: $411.0M
Last Round: $411.0M Series AJan 2025
Rounds: 1

About

Verdiva Bio is a clinical-stage biopharmaceutical company developing next-generation oral and injectable therapies for obesity and cardiometabolic disorders. Its lead asset VRB-101 is an oral, once-weekly GLP-1 peptide analog advancing through Phase 2 clinical trials, with additional pipeline programs including amylin agonists and combination therapies. The company launched in January 2025 with $411M in Series A financing and applies emerging gut-brain biology science to deliver more patient-friendly treatment options.

Summary

Verdiva Bio is a Life Sciences company based in London, United Kingdom, founded in 2024. It has raised $411.0M in total across 1 round, most recently a $411.0M Series A round in Jan 2025. Investors include Forbion Capital Partners, General Atlantic and RA Capital Management.